Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ: CORT) investors concerning the Company’s possible violations of federal securities laws.

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN CORCEPT THERAPEUTICS INCORPORATED (CORT), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.

Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at [e-mail], by telephone at [phone] or visit our website at www.howardsmithlaw.com.

What Happened?

On December 31, 2025, Corcept announced the U.S. Food and Drug Administration (“FDA”) had issued a Complete Response Letter (“CRL”), declining to approve the Company’s New Drug Application (“NDA”) for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism. The Company stated it was “surprised and disappointed by this outcome.”

On this news, Corcept’s stock price fell $35.40 per share, or 50.42%, to close at $34.80 per share on December 31, 2025.

Then, on January 29, 2026, the FDA published an updated CRL regarding Corcept’s relacorilant NDA. The updated letter revealed that “[d]uring the pre-submission meetings, [the FDA] informed [Corcept] on several occasions of [its] concerns about the adequacy of the clinical development program to assess the effect of relacorilant” and “to expect significant review issues if [Corcept] were to submit [its] application.”

On this news, Corcept’s stock price fell $4.71, or 10.6%, to close at $39.87 per share on January 30, 2026, thereby injuring investors.

Contact Us To Participate or Learn More:

If you purchased Corcept securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020,
Telephone: [phone]
Email: [e-mail]
Visit our website at: www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.